Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tom Kempe"'
Autor:
Kavitha Vemuri, Sanjeev Gangwar, Vangipuram S. Rangan, Mary Huber, Tom Kempe, Janette Sung, Colin Chong, Jennifer Juliano, Alice Stevens, Severino Cuison, Shrikant Deshpande, Meghan Greenbaum, Heng Cheng, Chetana Rao-Naik, Chin Pan, Qiang Cong, Jerry Jiang, Gregory D. Vite, Dan Dervin, David Passmore, Andrea L. Tatum, Eilene Kwok, Pina M. Cardarelli
Publikováno v:
Bioconjugate Chemistry. 31:2350-2361
Antibody-drug conjugates (ADCs) use antibodies to deliver cytotoxic payloads directly into tumor cells via specifically binding to the target cell surface antigens. ADCs can enhance the anti-tumor effects of antibodies, and increase the delivery of c
Autor:
Karla A. Henning, Chin Pan, Tanya Mulvey, Tom Kempe, Michelle Kuhne, Colin Chong, Fei Cao, Pina M. Cardarelli, Blake Belanger, Lewis J. Cohen, Sharline Chen, Wafa Niekro, Alan J. Korman
Publikováno v:
Clinical Cancer Research. 19:357-366
Purpose: CXCR4 has been identified as a prognostic marker for acute myeloid leukemia (AML) and other malignancies. We describe the development and characterization of a fully human antibody to CXCR4 and its application for therapy of AML, non–Hodgk
Publikováno v:
Personality and Individual Differences
According to traditional views of perfectionism, perfectionists are prone to experience shame and guilt and unable to experience pride. However, these views ignore that perfectionism is multidimensional and multifaceted. Consequently, the present stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6269df7c43381c8d5db01b93fa96d491
Autor:
Allen Zhang, Kavitha Vemuri, Charlie Cong, Shrikant Deshpande, Lourdes Thevanayagam, Andrea Tatum, Dan Derwin, Mohan Srinivasan, Peter Brams, Chetana Rao, Vangipuram S. Rangan, Mary Huber, Bilal Sufi, David Passmore, Sanjeev Gangwar, Tom Kempe, Janette Sung
Publikováno v:
Cancer Research. 70:2587-2587
MDX-1203 is a human anti-CD70 antibody conjugated to a pro-drug containing DNA alkylating cytotoxic Drug A. Drug A is composed of the anti-tumor compound Drug B, containing an ester linked protecting group, and a maleimide containing cleavable peptid